Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study

BMC Nephrology

Alberto Martinez Vea³  Manel Jariod²  Carmen Cabré³  Carmen García³  Ramon Font³  Merche Prats¹ 

[1] Servicio de Nefrología, Hospital Universitari de Tarragona Joan XXIII, Carrer del Doctor Mallafré Guasch 4, 43007, Tarragona, Spain;Unidad de Sistemas de Información de la Gestión, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain;Nephrology Service.Hospital Universitari de Tarragona Joan XXIII, Universitat Rovira i Virgili, Tarragona, Spain

关键词: Iron deficiency anaemia;    Hypophosphatemia;    Fibroblast growth factor 23;    Ferric carboxymaltose;    Chronic kidney disease;   

Others  :  1082872
DOI  :  10.1186/1471-2369-14-167

 received in 2013-03-14, accepted in 2013-07-12,  发布年份 2013

【 摘 要 】

Background

Some parenteral iron therapies have been found to be associated with hypophosphatemia. The mechanism of the decrease in serum phosphate is unknown. The aim of this study is to examine the effect of IV ferric carboxymaltose(FCM) on phosphate metabolism and FGF23 levels in patients with chronic kidney disease(CKD).

Methods

This is a post-hoc analysis of a prospective study carried out in 47 non-dialysis CKD patients with iron-deficiency anaemia who received a single 1000 mg injection of FCM. Markers of mineral metabolism (calcium, phosphate, 1,25-dihydroxyvitamin D, PTH and FGF23[c-terminal]) were measured prior to FCM administration and at week 3 and week 12 after FCM administration. Based on the measured levels of serum phosphate at week 3, patiens were classified as hypophosphatemic or non-hypophosphatemic.

Results

Serum phosphate levels decreased significantly three weeks after FCM administration and remained at lower levels at week 12 (4.24 ± 0.84 vs 3.69 ± 1.10 vs 3.83 ± 0.68 mg/dL, respectively, p < 0.0001. Serum calcium, PTH and 1,25-dihydroxyvitamin D did not change over the course of the study. Serum FGF23 decreased significantly from 442(44.9-4079.2) at baseline to 340(68.5-2603.3) at week 3 and 191.6(51.3-2465.9) RU/mL at week 12, p < 0.0001. Twelve patients were non-hypophosphatemic and 35 hypophosphatemic. FGF23 levels decreased in both groups, whereas no changes were documented in any of the other mineral parameters.

Conclusions

In non-dialysis CKD patients, FCM induces reduction in serum phosphate levels that persists for three months. FCM causes a significant decrease in FGF23 levels without changes to other bone metabolism parameters.

【 授权许可】

   
2013 Prats et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Hsu CY, McCulloch CE, Curhan GC: Iron status and haemoglobin level in chronic renal insufficiency. J Am Soc Nephrol 2002, 13:2783-2786.
• [2]Besarab A, Coyne DW: Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol 2010, 6:699-710.
• [3]Macdougall IC: Iron supplementation in the non-dialysis chronic kidney disease(ND-CKD) patients: oral or intravenous? Curr Med Res Opin 2010, 26:473-482.
• [4]Vaziri ND: Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013, 61:992-1000.
• [5]Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, Roy M, Machado G, Janklewicz P, Drahi G, Dahan H, Cohen Y: Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med 2012, 125:991-999.
• [6]Hörl WH: Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 2007, 18:382-393.
• [7]Auerbach M, Ballard H: Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010, 2010:338-347.
• [8]Covic A, Mircescu G: The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol Dial Transplant 2010, 25:2722-2730.
• [9]Lysen-Williamson KA, Keating GM: Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 2009, 69:739-756.
• [10]Grimmelt AC, Cohen CD, Fehr T, Serra AL, Wüthrich RP: Safety and tolerability of ferric carboxymaltose(FCM) for tratment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clin Nephrol 2009, 71:125-129.
• [11]Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD: A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011, 26:1599-15607.
• [12]Seid MH, Derman RJ, Baker JB, Bnach W, Goldberg C, Rogers F: Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol 2008, 199:435.e1-435.e7.
• [13]Van Wyck DB, Mangione AM, Morrison J, Hadley PE, Jehle JA, Goodnough LT: Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009, 49:2719-2728.
• [14]Charytan C, Bernardo MV, Koch TA, Butcher A, Morris D, Bregman DB: Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. Nephrol Dial Transplant 2013, 28:953-964.
• [15]Shimizu Y, Tada Y, Yamaucho M, Okamoto T, Suzuki H, Ito N, Fukumoto S, Sugimoto T, Fujita T: Hypophosphatemia induced by intravenous administration of saccharated ferric oxide. Another form of FGF23-related hypophosphatemia. Bone 2009, 45:814-816.
• [16]Shouten BJ, Hunt PJ, Livesy JH, Frampton CM, Soule SG: FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 2009, 94:2332-2337.
• [17]Imamura K: Effects of intravenous administration of iron preparations on the metabolism of phosphorus. Fukuoka Acta Med 1984, 75:316-326.
• [18]Kalra PA, Bock K, Meldal M: Iron isomaltoside 1000: a new high dose option for parenteral iron therapy. Port J Nephrol Hypert 2012, 26:13-24.
• [19]Mohammed S, Knoll S, Van Amberg A, Mennes PA: Cefotetan-induced haemolytic anemia causing severe hypophosphatemia. Am J Hematol 1994, 46:369-370.
• [20]Steiner M, Steiner B, Wilhelm S, Freund M, Schuff-Werner P: Severe hypophosphatemia during hematopoietic reconstitution after allogenic peripheral blood stem cell transplantation. Bone Marroww Transplant 2000, 25:1015-1016.
• [21]Sahara N, Tamashima S, Ihara M: Hereditary spherocytosis associated with severe hypophosphatemia in patients recovering from aplastic crisis. Rinsho Ketsueki 1998, 39:387-391.
• [22]Sanai T, Oochi N, Okada M, Imamura K, Okuda S, Ida M: Effect of saccharated ferric oxide and iron dextran on the metabolism of phosphorus in rats. J Lab Clin Med 2005, 146:25-29.
• [23]Sato K, Shiraki M: Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy. Endocrine J 1998, 45:431-439.
• [24]Hryszko T, Rydzewska-Rosolowska A, Brzoski S, Koc-Zorawska E, Mysliwiec M: Low molecular weight iron dextran increases fibroblast growth factor-23 concentration together with parathyroid hormone decrease in hemodialyzed patients. Ther Apher Dial 2012, 16:146-151.
• [25]Takeda Y, Komaba H, Goto S, Fuji H, Umezu M, Hasegawa H, Fujimori A, Nishioka M, Nishi S, Fukagawa M: Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am J Nephrol 2011, 33:421-426.
• [26]Prats M, Font R, Gutierrez , Nogués MR, Benito Y, Abejaro S, Garcia C, Romeu M, Martinez Vea A: Carboximaltosa férrica y estrés oxidativo en pacientes con enfermedad renal crónica prediálisis: efectos a corto y largo plazo. Nefrologia 2011, 31(Supp 2):58.
• [27]Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SH, Econs MJ: Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 2006, 91:2055-2061.
• [28]Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F: Chronic Kidney Disease Collaboration: sing standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006, 145:247-254.
• [29]Jahn MR, Andreasen HB, Fütterer S, Nawroth T, Schünemann V, Kolb U, Hofmeister W, Muñoz M, Bock K, Meldal M, Langguth P: A comparative study of the physicochemical properties of iron isomaltoside 1000(MonoferR), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011, 78:480-491.
• [30]Schoulten BJ, Doogue MP, Soule SG, Hunt PJ: Iron polymaltose-induced FGF23 elevation complicated by hypophosphatemic osteomalacia. Ann Clin Biochem 2009, 46:167-169.
• [31]Nankivell BJ, Boadle RA, Harris DCH: Iron accumulation in human chronic kidney disease. Am J Kidney Dis 1992, 20:580-584.
• [32]Nankivell BJ, Tay Y-C, Boadley RA, Harris DCH: Dietary protein alters tubular iron accumulation after partial nephrectomy. Kidney Int 1994, 45:1006-1013.
• [33]Tolouian R, Rajabi B, Boman D, Bilbao J, Gupta J: Iron infusion and deposition in the kidney. Clin Nephrol 2013, 79:237-240.
• [34]Zager RA, Johnson AC, Hanson SY: Parenteral iron nephrotoxicity: Potential mechanisms and consequences. Kidney In 2004, 66:144-156.
• [35]Deger SM, Erten Y, Pasaoglu OT, Derici UB, Reis KA, Onec K, Pasaoglu H: The effects of iron on FGF23-mediated Ca-P metabolism in CKD patients. Clin Exp Nephrol 2013, 17:416-423.
• [36]Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inove D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T: Clinical usefulness of measurement of fibroblast growth factor 23(FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone 2008, 42:1235-1239.
• [37]Wolf M, Koch TA, Bregman DB: Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 2013, 28:1793-1803.
• [38]Imel EA, Peacock M, Gray AK, Padgett LD, Hui SL, Econs MJ: Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 2011, 96:3541-3549.
• [39]Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE: Iron deficiency drives an autosomal dominant hypophosphatemic rickets(ADHR) phenotype in fibroblast growth factor-23(Fgf23) knock-in mice. Proc Natl Acad Sci USA 2011, 108:E1146-E1155.
• [40]Durham BH, Joseph F, Bailey LM, Fraser WD: The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commerical assays. Ann Clin Biochem 2007, 44:463-466.
• [41]Bhattacharyya N, Wiench M, Dumitrescu C, Connolly BM, Bugge TH, Patel HV, Gafni RI, Cherman N, Cho M, Hager GL, Collins MT: Mechanism of FGF23 processing in fibrous dysplasia. J Bone Miner Res 2012, 27:1132-1141.
• [42]Braithwaite B, Bruggraber SF, Prentice A: Intact fibroblast growth factor-23 and fragments in plasma from gambian children. Osteoporos Int 2013, 24:1121-1124.
• [43]Braithwaite B, Prentice AM, Doherty C, Prentice A: FGF23 is correlated with iron status but not with inflammation, and decrease after iron supplementation: a supplementary study. Int J Pediatr Endocrinol 2012, 1:27.
• [44]Yamasaki K, Hagiwara H: Excess iron inhibits osteoblast metabolism. Toxicol Lett 2009, 191:21-215.
• [45]Yang Q, Jian J, Abramson SB, Huang X: Inhibitory effects of iron on bone morphogenetic protein.2-induced osteoblastogenesis. J Bone Miner Res 2011, 26:1188-1196.
• [46]Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D: Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 2009, 150:4835-4845.
• [47]Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, pi M, Quarles LD: Fibroblast growth factor 23 is a counterregulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006, 17:1305-1315.
• [48]Hansen D, Rasmussen K, Pedersen SM, Rasmussen LM, Brandi L: Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Nephrol Dial Transplant 2012, 27:2263-2269.